PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
1-Year Return
2.57%
This Quarter Return
-11.87%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.29B
AUM Growth
-$271M
(-17%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-3.23%
Top 10 Holdings %
Top 10 Hldgs %
80.94%
Holding
37
New
–
Increased
7
Reduced
17
Closed
2
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$2.32M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
+$1.48M |
| 3 |
Karyopharm Therapeutics
KPTI
|
+$1.11M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$962K |
| 5 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$903K |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$8.16M |
| 2 |
United Therapeutics
UTHR
|
+$6.12M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$5.65M |
| 4 |
Biogen
BIIB
|
+$5.06M |
| 5 |
Align Technology
ALGN
|
+$4.84M |
Sector Composition
| 1 | Healthcare | 98.39% |
| 2 | Financials | 1.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rigel Pharmaceuticals
RIGL
$681M
| $1.95M | 0.15% |
65,240
| – | – |
|
27
Mirum Pharmaceuticals
MIRM
$3.73B
| $1.43M | 0.11% |
64,700
| – | – |
|
28
Dianthus Therapeutics
DNTH
$1.48B
| $1.25M | 0.1% |
27,019
| – | – |
|
|
ALIM
29
DELISTED
Alimera Sciences, Inc.
ALIM
| $1.13M | 0.09% |
200,919
| – | – |
|
30
Novavax
NVAX
$1.3B
| $921K | 0.07% |
12,500
| – | – |
|
31
Aldeyra Therapeutics
ALDX
$324M
| $715K | 0.06% |
160,800
| – | – |
|
32
Tactile Systems Technology
TCMD
$301M
| $546K | 0.04% |
27,100
| – | – |
|
|
KLDO
33
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $511K | 0.04% |
309,692
-31,338
| -9% | -$51.7K |
|
|
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $293K | 0.02% |
31,330
| – | – |
|
35
UroGen Pharma
URGN
$869M
| $213K | 0.02% |
24,500
| – | – |
|
36
AstraZeneca
AZN
$247B
| – | – |
-29,260
| Closed | -$1.7M |
|
|
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-183,800
| Closed | -$2.99M |
|